DANSPOT: A Multicenter Stepped-Wedge Cluster-Randomized Trial of the Reclassification of Acute Myocardial Infarction:...

Area of Science:

• Cardiology
• Biomarker Research
• Clinical Trials

Background:

• Cardiac troponins are key biomarkers for diagnosing acute myocardial infarction (AMI).
• International guidelines recommend sex-specific 99th percentile thresholds for troponins, but their clinical impact remains understudied.
• The DANSPOT study addresses this gap by evaluating the clinical effects of implementing these tailored thresholds.

Purpose of the Study:

• To assess the clinical impact of prospective implementation of population- and sex-specific diagnostic thresholds for cardiac troponins.
• To evaluate how these new thresholds affect diagnostics, treatment, and clinical outcomes in patients with myocardial infarction.

Main Methods:

• A nationwide, multicenter, stepped-wedge cluster-randomized trial involving 22 clinical centers in Denmark.
• Establishment of sex-specific troponin thresholds using a healthy Danish reference population for 5 assays.
• Sequential crossover from uniform to sex-specific thresholds, with a primary cohort of patients with suspected acute coronary syndrome.

Main Results:

• The study will compare the incidence of a composite outcome (nonfatal MI, revascularization, all-cause mortality) within 1 year.
• Outcomes will be analyzed separately for men and women before and after the implementation of sex-specific thresholds.
• The primary cohort includes patients with peak troponin values between current uniform and new sex-specific thresholds.

Conclusions:

• The DANSPOT Study is anticipated to demonstrate the clinical benefits of sex-specific troponin thresholds.
• Expected outcomes include improved diagnostics, treatment, and patient outcomes for myocardial infarction.
• Findings will be based on a national Danish reference population, providing relevant insights for clinical practice.